Search

• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. • Baricitinib used for 2 weeks was not associated with serious adverse events. Image, graphical abstract [ABSTRACT FROM AUTHOR]

• Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. • In baricitinib-treated patients no adverse events were recorded, after 2 weeks. • Clinical and respiratory parameters significantly improved at 2 weeks. • None of the baricitinib-treated patients required admission to ICU. • Proper control group was missing; this is required to demonstrate the efficacy. Image, graphical abstract [ABSTRACT FROM AUTHOR]